Health Literacy AsiaA groundbreaking study led by the Perelman School of Medicine at the University of Pennsylvania reveals that unvaccinated children and adolescents were up to 20 times more likely to develop long COVID than their vaccinated peers. Published in Lancet eClinicalMedicine, the study underscores that the primary protection afforded by COVID-19 vaccines lies in preventing infection itself, rather than mitigating the severity or likelihood of post-acute sequelae once infection has occurred.
Unraveling long COVID in the young
Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), continues to challenge researchers and clinicians alike. Characterized by lingering symptoms such as fatigue, cognitive difficulties, and shortness of breath weeks or even months after acute infection, long COVID remains poorly understood, with no universally effective treatment available. According to CDC estimates, as of mid-2022, approximately 7.5% of Americans, and over 9% of women, reported symptoms consistent with long COVID.
The Penn-led study offers one of the most comprehensive analyses of long COVID in youth populations to date, shedding new light on the extent to which vaccination can alter this risk trajectory.
“Vaccination has been key to preventing COVID-19 infection, which is important to reducing the risk of long COVID as well,” said senior author Yong Chen, PhD, professor of Biostatistics at Penn Medicine.
A nationwide cohort analysis
Drawing from the NIH’s RECOVER initiative, which aggregates electronic health records from healthcare systems across the U.S., the researchers conducted an observational study of nearly 400,000 children and adolescents. Three distinct cohorts were created based on age and the prevailing variant at the time:
- Delta Wave (July–November 2021): 112,590 adolescents (12–20 years)
- Omicron Wave (January–November 2022): 188,894 children (5–11 years); 84,735 adolescents (12–20 years)
During the Delta wave, the vaccine demonstrated 95% effectiveness in preventing long COVID among adolescents. Incidence rates were 0.11 per 10,000 person-weeks in vaccinated youth versus 3.54 in the unvaccinated—a 32-fold difference.
Against the Omicron variant in 2022, protection remained substantial, though slightly reduced:
- 60% effectiveness among vaccinated children (0.33 vs. 1.07 per 10,000 person-weeks)
- 75% effectiveness among vaccinated adolescents (0.24 vs. 1.43)
These statistics reflect a consistent pattern: the risk of long COVID in unvaccinated youth was significantly higher, particularly when the likelihood of infection was elevated.
Disentangling the mechanism: Prevention over mitigation
Using mediation analysis, the team sought to determine whether vaccination offered direct protection against long COVID after infection, or if its benefits were primarily tied to infection prevention. The results were clear.
“Once infection occurred, vaccinated individuals were no less likely to develop long COVID than their unvaccinated counterparts,” noted Qiong Wu, PhD, first author of the study and now an assistant professor at the University of Pittsburgh. “This suggests that the vaccine’s advantage lies in its ability to reduce the incidence of infection itself, thereby indirectly curbing long COVID cases.”
This finding reconciles previously inconsistent results from smaller studies, many of which failed to account for infection risk reduction as a confounding factor.
A call for continued vigilance
While long COVID has been predominantly studied in adults, this research places a spotlight on the unique vulnerabilities of children and adolescents. “Their immune responses to both the virus and vaccines may differ from adults, and understanding those differences is crucial,” explained co-author Jeffrey Morris, PhD, Director of Biostatistics.
With no definitive treatment for long COVID and continued viral circulation globally, the study reinforces a critical message: prevention through vaccination remains the most effective strategy to protect the long-term health of young people.
“This study provides compelling evidence to support sustained pediatric vaccination efforts,” said co-senior author Christopher Forrest, MD, PhD, of the Children’s Hospital of Philadelphia. “In the absence of curative therapies, reducing exposure to SARS-CoV-2 is our best defense.”
Funding and future directions
This research was supported by multiple grants from the National Institutes of Health and the Patient-Centered Outcomes Research Institute, reflecting the growing national priority to understand and mitigate long COVID’s impact. As the RECOVER initiative continues, future studies are expected to delve deeper into the biological mechanisms of PASC and explore targeted strategies for prevention and treatment.
In a post-pandemic world still reckoning with the enduring shadow of SARS-CoV-2, these findings offer a vital piece of clarity: vaccination is not just a shield against severe acute disease; it’s also a critical barrier against the prolonged, often debilitating aftermath of COVID-19 in our youngest populations. (Source: Penn Medicine News)
By Global Health Press
logesan
